1 PK/PD modeling within regulatory submissions Is it used? Can it be used and if yes, where? Views from industry 24 September 2008.

Slides:



Advertisements
Similar presentations
The Drug Discovery Process
Advertisements

Matthew M. Riggs, Ph.D. metrum research group LLC
Development of Evaluation and Consultation on Bridging Studies: Thailand Experiences Suchart Chongprasert, Ph.D. Investigational New Drug Subdivision Food.
Randomized Controlled Trial
PHT 415 BASIC PHARMACOKINETICS Course Instructor:Prf. Dr. Hnaa elsaghir Assistant lecturers, Doaa elshora and eman elfakih Text: Hand book of basic pharmacokinetics,
Pharmacotherapy in the Elderly Judy Wong
+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.
Neonatal/Juvenile Animal Safety Studies Kenneth L. Hastings, Dr.P.H., D.A.B.T. Office of New Drugs, CDER.
Career Opportunities for PharmDs in the Pharmaceutical Industry: Research & Development.
Biomedical research methods. What are biomedical research methods? An integrated approach using chemical, mathematical and computer simulations, in vitro.
“FUTURE CONSIDERATIONS FOR PK/PD RESEARCH” Terrence F. Blaschke, M.D. Professor of Medicine and Molecular Pharmacology Stanford University.
Bioequivalence of Topical Drug Products
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.
Why are we learning this? How scientific knowledge (pharmacology, therapeutics) and clinical skills (measuring blood pressure, glucoses, drug information)
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 In Vitro/Animal Models to Support Dosage Selection: FDA Perspective.
PK/PD of Antibiotics in relation to resistance Otto Cars MD Department of Medical Sciences Infectious diseases Uppsala University Sweden.
Nonclinical Perspective on Initiating Phase 1 Studies for Small Molecular Weight Compounds John K. Leighton, PH.D., DABT Supervisory Pharmacologist Division.
Clinical Pharmacy Part 2
CHEE DRUG PRODUCT DEVELOPMENT u Drug ä agent intended for use in the diagnosis, mitigation, treatment, cure, or prevention of disease in man or animals.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
© 2012 The McGraw-Hill Companies, Inc. All rights reserved. 1 Pharmacology: An Introduction CHAPTER.
PK/PD Modeling in Support of Drug Development Alan Hartford, Ph.D. Associate Director Scientific Staff Clinical Pharmacology Statistics Merck Research.
Concepts and Applications of Pharmacokinetics
 1. A care plan is developed for each of the patient's medical conditions being managed with pharmacotherapy.  2. A goal of therapy is the desired response.
Orientation to Pharmacology
1 Axcan Public Presentation for the FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting July 23, 2008.
Biomedical Research. What is Biomedical Research Biomedical research is the area of science devoted to the study of the processes of life; prevention.
FARMAKOKINETIKA. INTRODUCTION Historically, pharmaceutical scientists have evaluated the relative drug availability to the body in vivo after giving a.
EMEA London Pharmacokinetic- pharmacodynamic integration in veterinary drug development: an overview P.L. Toutain National Veterinary School ;Toulouse.
Federal Institute for Drugs and Medical Devices The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health (BMG) The use of.
Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April Quantitative risk analysis using exposure-response.
Bioequivalence of Locally Acting Gastrointestinal Drugs: An Overview
CHEE 4401 Definitions drug - any substance that affects the structure or functioning of an organism pharmaceutics - the area of study concerned with the.
Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.
Regulatory Aspects of PK/PD – (modelling) Karolina Törneke Senior expert, member of the CVMP.
INTRODUCTION CLINICAL PHARMACOKINETICS
1 Pharmacokinetics: Introduction Dr Mohammad Issa.
European Patients’ Academy on Therapeutic Innovation The key principles of pharmacology.
Introduction to Pharmacology Yacoub Irshaid MD, PhD, ABCP Department of Pharmacology.
Regulatory Considerations for Endpoints Ann T. Farrell, M.D. FDA/CDER/DODP.
PHT 415 BASIC PHARMACOKINETICS
Improvement in Dose Selection Through Clinical PK/PD in Antimicrobial Drug Development: Perspective of an Industry PK/PD Scientist Gregory A. Winchell,
Clinical Trials - PHASE II. Introduction  Important part of drug discovery process  Why important??  Therapeutic exploratory trial  First time in.
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 Current Status of Dose Selection in Antimicrobial Drug Development.
1 Biopharmaceutics Dr Mohammad Issa Saleh. 2 Biopharmaceutics Biopharmaceutics is the science that examines this interrelationship of the physicochemical.
1 CHAPTER 2 DEFINITIONS RELATED TO PHARMACOKINETICS.
My Industrial Placement 15 th February Where I work Company: Pfizer Pfizer is the world’s largest research-based pharmaceutical company Division:
Copyright © 2008 Merck & Co., Inc., Whitehouse Station, New Jersey, USA All rights Reserved Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Raltegravir.
| 1 Application of a Bayesian strategy for monitoring multiple outcomes in early oncology clinical trials Application of a Bayesian strategy for monitoring.
Section I General principle of Pharmacology. Where can you get information about general principle of Pharmacology?  Text books:  Katzung, Basic and.
The Stages of a Clinical Trial
Chapter 8 BIOAVAILABILITY & BIOEQUIVALENCE
Introduction of Biopharmaceutics & Pharmacokinetics
Overview of Standard Phase II Design Issues
Biopharmaceutics Dr Mohammad Issa Saleh.
Simone M. Shurland, Ph.D., Division of Anti-Infective Products
Biomedical Research.
5 Pharmacodynamics.
Orientation to Pharmacology
Clinical Pharmacokinetics
RESEARCH & INNOVATION SHOWCASE Prof William Hope
CTD Module 4: Non-Clinical Studies SPC Relevant Scientific information
بسم الله الرّحمن الرّحيم. Dr Sima Sadrai TUMS
My typical day as a scientist in pre-clinical at AZ/MedI
Therapeutic Drug Monitoring chapter 1 part 1
Selvadurai Muralidharan, Kalaimani Jaya Raja Kumar
Introduction to Pharmacogenetics
Drug Therapy in Pediatric Patients
Considerations for Successful Biopharmaceutical Product Development: Discovery to Proof of Concept -A Panel Discussion Stanley C. McDermott, PharmD, MS,
Presentation transcript:

1 PK/PD modeling within regulatory submissions Is it used? Can it be used and if yes, where? Views from industry 24 September 2008

2 Introduction toolassistPK/PD modeling offers a valuable tool to assist in some cases with establishing an effective dose and dosing regimen. PK/PD modeling is mostly used in the research and early development phases –relationship between PK and efficacy –may also be used in development when PK/PD models are well established and recognized both by the regulatory authorities and the scientific community Interpretation is controversial and a general definition is still missing and under considerable discussion.

3 Treatment Regimen What do we need to know to determine dose, route, and frequency? –Host physiology; –Pharmacokinetics; –Pharmacodynamics. The end results should be a safe and realistic dosage regimen – interval the clinician or owner will obey.

4 Remember: Rational Design of Safe and Effective Dosage Regimen(s) Require Knowledge and Judgment ! Dosage Regimen Activity-Toxicity Therapeutic Window Side Effects Toxicity Concentration-Response Pharmacokinetics Absorption Distribution Metabolism Excretion Clinical Factors Weight Condition being treated Other disease states Multiple Drug Therapy Convenience of Regimen Other Factors Route of Administration Dosage Form Breed Cost ELDU Resistance

5 Limitations When a disease model is not available, PK/PD can only be done on clinical cases with the limitations of variability, number of blood samples and endpoint/efficacy measurement. When a PK/PD modeling is possible, the model must be chosen to reflect as far as possible the disease pattern and severity or be recognised in the specific literature. There may be clinical conditions where a PK/PD model will not result in an effective method to predict clinical outcomes (e.g. plasma concentration do not reflect PD action). Reliable PK/PD relationship very often only are established at the end of the development program.

6 Limitations (cont’) Ideally the model will be based on a complete range of responses requiring appropriate designed studies which may not always be practical. For antibiotics surrogate markers were developed in immunocompromised animals and only for specific bug drug combinations. In addition, the MIC is a useful but imprecise parameter, measured in vitro. Simple and sometimes unrealistic assumptions are critical in biological models. Hence “all models are wrong, but some are more useful than others” and applying PK/PD alone can lead to unncessarily high doses.

7 Advantages PK/PD may replace a dose determination study saving time, reducing costs and use of animal testing. PK/PD data are helpful in case of field trial license applications and in supporting line extensions for well established products. PK/PD can be used to simulate efficacy/safety outcomes in different routes and doses, to minimise additional animal experiments.

8 What sort of training is required for PK/PD assessment? PK/PD modeling should be performed by scientists with a strong background in pharmacometrics: statistics, pharmacokinetics and a firm understanding of the mechanisms of PD models. While human PK/PD training will allow for understanding of PK/PD models, an understanding of comparative physiology (veterinary pharmacology) is essential to interpreting the results and limitations of these models.

9 CONCLUSIONS PK/PD modeling should be accepted when available but must not be systematically requestedFor regulatory submissions, PK/PD modeling should be accepted when available but must not be systematically requested. PK/PD should not be a tool to assess the efficacy of well established products that have demonstrated efficacy under normal conditions of use and for which there are no pharmacovigilance alerts or changing resistance rates. a substitution, but not an additional requirement.When feasible, PK/PD data should be considered a substitution, but not an additional requirement. –The conditions under which PK/PD modeling can substitute other methods should be clarified. PK/PD reports should be signed by authors with strong knowledge and background on comparative physiology statistics, pharmacokinetics, pharmacology, toxicology, clinical models, etc.